UCARE (Urology Cancer Research and Education) is an independent charity committed to improving the treatment and care of cancer patients through research and education.  I went along this evening to an event where three researchers spoke about how funding from UCARE has really helped them to make progress in cancer research and treatment.

UCARE (Urology Cancer Research and Education) is a local independent charity founded by a group of clinicians, patients and supporters who care about fighting urological cancers, those of the kidney, bladder, prostate and testes.

Treating people with urological cancers continues to be a major challenge, 20% of all new cancers diagnosed each year will be a urological cancer; 54,000 new urological cancers are diagnosed each year – 10,000 cases more than breast cancer. Despite the frequency of diagnosis of these cancers, they receive little detailed or sustained media coverage and consequently no information enters the public consciousness.

We know that with early diagnosis more people than ever could survive the disease. Awareness of the signs and symptoms of these cancers remains woefully low amongst the general public. With early detection and diagnosis many more people could survive. There are known to be gaps in cancer survival rates between the UK and its European counterparts, and it is recognised that the primary reason for this is late diagnosis.
Research and awareness go hand in hand, so the health care needs of the community are at the forefront of the UCARE charitable object. Our part in educating the public on what to look for in the signs and symptoms of urological cancers, to help people make improved life style choices, and to give advice on seeking early intervention is vital. Since health awareness campaigns in the UK encouraged women to ‘know their bodies’, mortality rates for breast cancer, have fallen dramatically. Women are aware that they must seek early intervention. A higher public profile has resulted in more funds for research leading to new and more effective treatments and we aim that UCARE will have the same impact for urological cancers.

I didn’t have to speak at this event but was really impressed at how sometimes quite modest funding can enable work to continue or be started that enables much larger amounts of funding to be achieved from larger bodies.  Oxford is one of the world’s leading centres of cancer research and treatment so I was very pleased to be at the event to represent the City of Oxford and offer its full support to the excellent work of UCARE.